Laser Removal of Age (Sun) Spots on Hands (NCT01885871) | Clinical Trial Compass
CompletedNot Applicable
Laser Removal of Age (Sun) Spots on Hands
United States20 participantsStarted 2013-06
Plain-language summary
The purpose of this study is to determine whether picosecond laser is effective in the treatment of age (sun) spots.
Who can participate
Age range18 Years – 60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Females or Males, 18 to 60 years of age (inclusive).
* Fitzpatrick Skin Type I - III (Appendix 2).
* Clinical diagnosis of benign solar lentigines of the hands.
* Presence of at least 5 lesions in the treatment area in diameters ranging from 1 to 8 mm.
* Has not used any prescription or over the counter topical creams (e.g., hydroquinone, and/or retinoids and/or corticosteroids) used in the treatment of pigmentation in the treatment area within the last 4 weeks.
* Willing to refrain from using any prescription or over the counter topical creams used for the treatment of pigmentation (e.g., hydroquinone, and/or retinoids and/or corticosteroids) in the treatment area during the study period.
* Must be able to read, understand and sign the Informed Consent Form.
* Willing and able to adhere to the treatment and follow-up schedule and before and after treatment care instructions.
* Willing to protect and/or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher in the treatment area starting up to 4 weeks before the treatment, every day for the duration of the study, including the follow-up period
* Willing to have digital photographs taken of the treatment area
* Agree not to undergo any other procedure(s) for the treatment of solar lentigines during the study.
* Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at last 3 months prior to enrollment and during the entire course of the s…
What they're measuring
1
Median VAS Improvement Score as Assessed by Blinded Physician Reviewers